Where will innovation come from in the metabolic drug pipeline? What clinical strategies will satisfy regulators?
Answering these questions holds the key to dominating the enormous and expanding cardiometabolic market.
Continuing unmet medical need, bottlenecks in the pipeline and a harsh regulatory climate remain strong drivers for enhancing your metabolic drug development strategy.
By giving you unparalleled access to the minds behind the most promising drugs in development, Metabolic Disease Drug Development will provide the perfect platform to address these concerns and direct your preclinical and clinical development strategy.
Metabolic Disease Drug Development guarantees strong representation and candid discussion from senior level figures at Pfizer, Merck, BMS and the most innovative biotechs in the field. It will provide valuable insight into identifying and validating new metabolic drug targets, streamlining clinical strategy and speeding the passage of your drugs to market.
Drug developers focusing on developing novel metabolic drugs
Scientists and academics working in diabetes, obesity and dyslipidemia
Clinicians and CROs specializing in metabolic drug trials
“That was the best event I have ever attended. I don’t usually consider commercial events but that was very good. You have a committed customer from this point onwards” Sanofi
“Strong program, great speakers and a genuine focus on identifying solutions” Novartis
“A great place to get the latest information and networking” Pfizer
“Very valuable. Good mix of scientists & developers” Boehringer-Ingelheim
“An exciting set of insightful talks on a broad array of topics” Eli Lilly
“It exceeded my expectations. The talks were high quality and the interaction among participants was excellent.” Genentech